For immediate release: 22 August 2019
Oxford Cancer Biomarkers (OCB) have hired two Senior Operations and Quality Control Specialists to manage their continued growth, following accelerating adoption of their ToxNav genetic blood test that predicts patients’ susceptibility to 5FU or capecitabine severe toxicity, prior to treatment. Together, they aim to further enhance process, automation and efficiency at OCB.
Pawel Wolyniec is the Senior Quality Control Specialist at OCB, where he performs extensive quality assurance activities, including drafting quality documents and policies, overseeing
the Quality Management System and ensuring ongoing compliance with quality and industry regulatory requirements. With more than 10 years of experience working in a laboratory environment and at a MHRA certified site, he brings additional rigour, working to ISO17025, ISO13485 standards. Pawel has previously been responsible for operations oversight, R&D test design, quality assurance activities, customer consultations and managerial activities as part of a management team.
Gary Whitehouse has joined OCB as the Operations Specialist, aiming to increase efficiency and ensuring that the back-end of the company functions as smoothly as possible. He graduated from Keele in 2017 with a Chemistry degree, and since then has worked in various manufacturing and quality control roles in both small and large-scale companies.
Further information contact:
Paul Blackburn, Certatim Consulting on behalf of Oxford Cancer Biomarkers